Deal snapshot: Rodeo’s preclinical work in modulating the 15-PDGH enzyme may yield novel regenerative therapies for inflammation, Amgen says, including GI and post-bone marrow transplant indications.
Who: Amgen/Rodeo Therapeutics
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
